» Articles » PMID: 23619564

Modeling Tumor-host Interactions of Chronic Lymphocytic Leukemia in Xenografted Mice to Study Tumor Biology and Evaluate Targeted Therapy

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2013 Apr 27
PMID 23619564
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, the B-cell receptor (BCR) and nuclear factor- κB (NF-κB) pathways are activated in the lymph node (LN) microenvironment. Thus, model systems mimicking tumor-host interactions are important tools to study CLL biology and pathogenesis. We investigated whether the recently established NOD/scid/γc(null) (NSG) mouse xenograft model can recapitulate the effects of the human microenvironment. We assessed, therefore, tumor characteristics previously defined in LN-resident CLL cells, including proliferation, and activation of the BCR and NF-κB pathways. We found that the murine spleen (SP) microenvironment supported CLL cell proliferation and activation to a similar degree than the human LN, including induction of BCR and NF-κB signaling in the xenografted cells. Next, we used this model to study ibrutinib, a Bruton's tyrosine kinase inhibitor in clinical development. Ibrutinib inhibited BCR and NF-κB signaling induced by the microenvironment, decreased proliferation, induced apoptosis and reduced the tumor burden in vivo. Thus, our data demonstrate that the SP of xenografted NSG mice can, in part, recapitulate the role of the human LN for CLL cells. In addition, we show that ibrutinib effectively disrupts tumor-host interactions essential for CLL cell proliferation and survival in vivo.

Citing Articles

Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing.

Bertilaccio M, Chen S Front Immunol. 2024; 15:1376660.

PMID: 38903501 PMC: 11186982. DOI: 10.3389/fimmu.2024.1376660.


Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.

Mhibik M, Gaglione E, Eik D, Herrick J, Le J, Ahn I Blood Adv. 2023; 7(15):4089-4101.

PMID: 37219524 PMC: 10388733. DOI: 10.1182/bloodadvances.2022009517.


NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.

Zhang D, Harris H, Chen J, Judy J, James G, Kelly A Blood. 2022; 141(13):1584-1596.

PMID: 36375120 PMC: 10163313. DOI: 10.1182/blood.2022016934.


In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Hoferkova E, Kadakova S, Mraz M Cancers (Basel). 2022; 14(13).

PMID: 35804862 PMC: 9264798. DOI: 10.3390/cancers14133087.


International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.

Awan F, Addison D, Alfraih F, Baratta S, Campos R, Cugliari M Blood Adv. 2022; 6(18):5516-5525.

PMID: 35790105 PMC: 9631706. DOI: 10.1182/bloodadvances.2022007938.


References
1.
Bichi R, Shinton S, Martin E, Koval A, Calin G, Cesari R . Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002; 99(10):6955-60. PMC: 124510. DOI: 10.1073/pnas.102181599. View

2.
Luqman M, Klabunde S, Lin K, Georgakis G, Cherukuri A, Holash J . The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008; 112(3):711-20. PMC: 2481542. DOI: 10.1182/blood-2007-04-084756. View

3.
Muzio M, Scielzo C, Bertilaccio M, Frenquelli M, Ghia P, Caligaris-Cappio F . Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2008; 144(4):507-16. DOI: 10.1111/j.1365-2141.2008.07475.x. View

4.
Rosenwald A, Wright G, Wiestner A, Chan W, Connors J, Campo E . The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003; 3(2):185-97. DOI: 10.1016/s1535-6108(03)00028-x. View

5.
de Rooij M, Kuil A, Geest C, Eldering E, Chang B, Buggy J . The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012; 119(11):2590-4. DOI: 10.1182/blood-2011-11-390989. View